Company focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics business and other non-core assets. LAVAL, Canada and CAMBRIDGE, England, Jan. 27, 2021...
from PR Newswire: https://ift.tt/3r3RelH
No comments:
Post a Comment